Join, Follow & Connect
Join Modern Healthcare's LinkedIn group Follow Modern Healthcare on Twitter Join Modern Healthcare's Facebook group Follow Modern Healthcare's Pinterest board Modern Healthcare's Flickr page Modern Healthcare's YouTube Channel Get a Modern Healthcare news feed

 
Comment Buy Reprints Print Article Share on LinkedIn Share on Facebook Share on Twitter Email this page to a colleague
Healthcare Business News
 

Rule would let CMS terminate poor-performing Advantage, Part D sponsors


By Jessica Zigmond
Posted: October 3, 2011 - 12:01 am ET
Tags:

CMS on Monday proposed changes to the Medicare Advantage and prescription drug programs that would implement provisions outlined in last year's Patient Protection and Affordable Care Act.

Advertisement | View Media Kit

 

Open to a 60-day comment period, the proposed rule would provide the CMS with the authority to terminate poor-performing Medicare Advantage and Part D sponsors that fail to achieve at least a 3-star rating under the agency's 5-star plan rating system for a period of three years.

It would also allow fully integrated, dual eligible, special-needs plans, or SNPs, to offer supplemental benefits beyond those that exist currently for Medicare Advantage plans for patients who are eligible for both Medicare and Medicaid. These benefits include non skilled-nursing activities in the home and in-home food delivery for vulnerable patients, according to CMS.

Meanwhile, the proposed rule would require Medicare part D sponsors in certain cases to provide the option of a daily, pro-rated, cost-sharing rate for prescriptions for fewer than 30 days. And if a prescription is denied by a part D plan, the proposed rule would allow physicians to request reconsiderations with the independent review entity, or IRE, on their patient's behalf without obtaining a signed authorized representative form.

The regulation would also require pharmacy benefit managers under part D to report additional financial information in order to improve transparency.

“These changes would improve data collection and tracking, help better identify the prescriber of part D medications, and assist our law enforcement partners in the conduct of investigations when there is suspected fraud association with a prescription drug claim,” said a summary of the rule from CMS.

If it's made final, the rule would be effective in 2013.


What do you think?

Share your opinion. Send a letter to the Editor or Post a comment below.

Post a comment

Loading Comments Loading comments...

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.